While all cholangiocarcinoma subtypes share several somatic mutations, including TP53 and KRAS, recent next-generation sequencing has identified unique genetic aberrations dependent on the CCA subtype [62]. This evidence concerns the gene TP53 and cholangiocarcinoma.